United Therapeutics Corporation $UTHR Shares Acquired by Employees Retirement System of Texas

Employees Retirement System of Texas boosted its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 693.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,832 shares of the biotechnology company’s stock after purchasing an additional 2,475 shares during the period. Employees Retirement System of Texas’ holdings in United Therapeutics were worth $1,380,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in UTHR. Torren Management LLC acquired a new stake in United Therapeutics during the 4th quarter valued at $26,000. Activest Wealth Management grew its holdings in United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares in the last quarter. WealthCollab LLC grew its holdings in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. grew its holdings in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares in the last quarter. Finally, Entrust Financial LLC bought a new position in United Therapeutics during the 4th quarter valued at $31,000. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Price Performance

NASDAQ UTHR opened at $570.75 on Thursday. The company’s fifty day moving average price is $565.54 and its two-hundred day moving average price is $514.75. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35. The company has a market capitalization of $24.23 billion, a price-to-earnings ratio of 21.07, a price-to-earnings-growth ratio of 1.87 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. During the same quarter in the previous year, the business posted $6.63 earnings per share. The company’s quarterly revenue was down 1.6% compared to the same quarter last year. As a group, analysts anticipate that United Therapeutics Corporation will post 27.07 EPS for the current year.

Insider Activity

In other news, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00. Following the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $9,956,712.48. This trade represents a 34.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last 90 days, insiders have sold 581,973 shares of company stock valued at $325,968,044. Company insiders own 8.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Cantor Fitzgerald increased their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. Finally, UBS Group increased their price objective on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $619.42.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.